VSV IFNbeta NIS

Drug Profile

VSV IFNbeta NIS

Alternative Names: VSV-IFNβ-NIS; VSV-IFNβ-NIS - Vyriad

Latest Information Update: 23 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vyriad
  • Developer Mayo Clinic; National Cancer Institute (USA); Vyriad
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Endometrial cancer; Multiple myeloma; Myeloid leukaemia; Solid tumours; T cell lymphoma

Most Recent Events

  • 15 Sep 2017 Phase-I clinical trials in Endometrial cancer (Late-stage disease, Metastatic disease, Recurrent) in USA (IV) (NCT03120624)
  • 17 Apr 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT02923466)
  • 04 Apr 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT03017820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top